Context Therapeutics' (CNTX) Buy Rating Reaffirmed at D. Boral Capital

Key Points

• D. Boral Capital has reiterated a "buy" rating for Context Therapeutics (CNTX), with a target price of $9.00, amid several positive ratings from other analysts.
• Context Therapeutics reported a quarterly loss of ($0.09) earnings per share, missing analysts' consensus estimates, and is projected to post a -0.51 EPS for the current fiscal year.
• Recent insider activity includes CEO Martin A. Lehr purchasing 100,000 shares at $0.70 per share, indicating a 12.19% increase in his position, while the company has seen a total insider purchase of 160,010 shares recently.

Context Therapeutics (NASDAQ:CNTX - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at D. Boral Capital in a report issued on Thursday,Benzinga reports. They currently have a $9.00 target price on the stock.

Several other equities analysts have also issued reports on the stock. Piper Sandler reiterated an "overweight" rating and set a $4.00 target price (down from $4.50) on shares of Context Therapeutics in a report on Thursday, June 26th. William Blair restated an "outperform" rating on shares of Context Therapeutics in a report on Tuesday, April 29th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Context Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $5.25.

Context Therapeutics Price Performance

CNTX traded down $0.02 on Thursday, hitting $0.70. The company had a trading volume of 63,860 shares, compared to its average volume of 198,900. Context Therapeutics has a 52-week low of $0.49 and a 52-week high of $2.75. The stock has a fifty day simple moving average of $0.69 and a 200-day simple moving average of $0.75. The firm has a market capitalization of $62.61 million, a P/E ratio of -1.94 and a beta of 1.89.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). Equities research analysts expect that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Martin A. Lehr bought 100,000 shares of the company's stock in a transaction that occurred on Monday, June 9th. The stock was bought at an average price of $0.70 per share, with a total value of $70,000.00. Following the acquisition, the chief executive officer owned 920,190 shares of the company's stock, valued at approximately $644,133. This represents a 12.19% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Jennifer Lynn Minai-Azary bought 40,010 shares of the company's stock in a transaction that occurred on Friday, June 6th. The stock was purchased at an average cost of $0.64 per share, with a total value of $25,606.40. Following the acquisition, the chief financial officer directly owned 80,010 shares in the company, valued at $51,206.40. This trade represents a 100.03% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 160,010 shares of company stock valued at $107,206. Company insiders own 2.80% of the company's stock.

Hedge Funds Weigh In On Context Therapeutics

Several institutional investors have recently added to or reduced their stakes in CNTX. Jane Street Group LLC purchased a new stake in Context Therapeutics during the fourth quarter valued at $29,000. Citadel Advisors LLC purchased a new position in Context Therapeutics in the fourth quarter worth about $31,000. Millennium Management LLC grew its position in Context Therapeutics by 24.2% in the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company's stock worth $188,000 after acquiring an additional 34,835 shares in the last quarter. Shay Capital LLC purchased a new position in Context Therapeutics in the fourth quarter worth about $52,000. Finally, Geode Capital Management LLC raised its position in Context Therapeutics by 9.2% in the 4th quarter. Geode Capital Management LLC now owns 628,729 shares of the company's stock worth $661,000 after purchasing an additional 52,830 shares during the period. Hedge funds and other institutional investors own 14.03% of the company's stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.